NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Health Technology Appraisal

Review proposal of NICE Technology Appraisal Guidance nos. 47, on the use of glycoprotein Ilb/Illa inhibitors for acute coronary syndromes, & 80, clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome.

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Eli Lilly and Company Ltd (abciximab)	Age Concern Cymru
GlaxoSmithKline (eptifibatide)	Board of Community Health Councils in
Merck Sharp & Dohme Ltd (tirofiban)	Wales
Bristol-Myers Squibb (clopidogrel)	British National Formulary
Sanofi-Aventis (clopidogrel)	 Cardiovascular Diseases Specialist Library (CVDSL)
Patient/carer groups	 Department of Health, Social Services
Action Heart	and Public Safety for Northern Ireland
Age Concern England	 Medicines and Healthcare products
British Cardiac Patients Association	Regulatory Agency (MHRA)
British Heart Foundation	 National Public Health Service for
Circulation Foundation	Wales
Coronary Prevention Group	NHS Confederation
Counsel and Care	 NHS Purchasing and Supply Agency
Healthy Heart UK	NHS Quality Improvement Scotland
HEART UK	Scottish Medicines Consortium
 Heart Care Partnership (UK) 	0
Help the Aged	Comparator manufacturers
 National Heart Forum (UK) 	Bristol-Myers Squibb (clopidogrel)
South Asian Health Foundation	Sanofi-Aventis (clopidogrel)
Specialised Healthcare Alliance	Eli Lilly and Company Ltd (abciximab)
	GlaxoSmithKline (eptifibatide)
Professional groups	Merck Sharp & Dohme Ltd (tirofiban)
British Association for Nursing in	Polovant recognish aroung
Cardiac Care	Relevant research groups
 British Association for Services to the Elderly 	 Antithrombotic Trialists' (ATT) Collaboration
British Association of Emergency	British Society for Cardiovascular Research
Medicine	Cardiac and Cardiology Research
British Cardia Intervention Society British Cardia Vacantler Society	Dept, Barts and The London
British Cardiovascular Society British Cardiovascular Society	Cardiovascular Research Initiative,
British Geriatrics Society Callege of Emergency Medicine	University of Oxford
College of Emergency Medicine	Chirolony of Children

National Institute for Health and Clinical Excellence

Review proposal of NICE Technology Appraisal Guidance nos. 47, on the use of glycoprotein IIb/IIIa inhibitors for acute coronary syndromes, & 80, clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome.

Issue date: July 2007 Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
 National Association of Primary Care Primary Care Cardiovascular Society Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians' Cardiology Committee Royal Pharmaceutical Society Royal Society of Medicine Cardiothoracic Section Royal Society of Medicine – Intellectual Disabilities Forum Society for Cardiological Science and Technology The Vascular Society Society of Cardiothoracic Surgeons United Kingdom Clinical Pharmacy Association 	 Cochrane Heart Group CORDA National Heart Research Fund Research Institute for the Care of the Elderly Assessment team National Coordinating Centre for Health Technology Assessment Associated Guideline Groups National Collaborating Centre for Chronic Conditions National Collaborating Centre for Primary Care
OthersDepartment of Health	
Northumberland Care TrustTorbay Care TrustWelsh Assembly Government	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: July 2007 Page 2 of 3

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

Issue date: July 2007 Page 3 of 3